Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma

Fig. 3

Associations of tumor-specific T cell infiltration and pancreatic cancer tumor subtype with the best overall response. a DEG plots between patients with PR versus SD and between patients with SD versus PD. b Association of genes involved in T cell-mediated immune responses with the best overall response. c Association of pancreatic cancer tumor subtype with the best overall response. Totally, 38 patients were included in these analyses, including 13 patients with PR, 18 patients with SD, and 7 with PD. In the boxplot, the bars represent whiskers, the range of the data. p values are nominal. DEG differentially expressed gene, PR partial response, SD stable disease, PD progressive response, FC fold change, RSEM RNA-Seq by expectation-maximization

Back to article page